scispace - formally typeset
Journal ArticleDOI

Purification and cloning of amyloid precursor protein beta-secretase from human brain.

Reads0
Chats0
TLDR
A membrane-bound enzyme activity that cleaves full-length APP at the β-secretase cleavage site is described and found to be the predominant β-cleavage activity in human brain, and it is found that human brain β- secretase is a new membrane- bound aspartic proteinase.
Abstract
Proteolytic processing of the amyloid precursor protein (APP) generates amyloid β (Aβ) peptide, which is thought to be causal for the pathology and subsequent cognitive decline in Alzheimer's disease Cleavage by β-secretase at the amino terminus of the Aβ peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of β-cleaved soluble APP1, and a corresponding cell-associated carboxy-terminal fragment Cleavage of the C-terminal fragment by γ-secretase(s) leads to the formation of Aβ The pathogenic mutation K670M671 → N670L671 at the β-secretase cleavage site in APP2, which was discovered in a Swedish family with familial Alzheimer's disease, leads to increased β-secretase cleavage of the mutant substrate3 Here we describe a membrane-bound enzyme activity that cleaves full-length APP at the β-secretase cleavage site, and find it to be the predominant β-cleavage activity in human brain We have purified this enzyme activity to homogeneity from human brain using a new substrate analogue inhibitor of the enzyme activity, and show that the purified enzyme has all the properties predicted for β-secretase Cloning and expression of the enzyme reveals that human brain β-secretase is a new membrane-bound aspartic proteinase

read more

Citations
More filters
Journal ArticleDOI

Alzheimer's Disease: Genes, Proteins, and Therapy

TL;DR: Evidence that the presenilin proteins, mutations in which cause the most aggressive form of inherited AD, lead to altered intramembranous cleavage of the beta-amyloid precursor protein by the protease called gamma-secretase has spurred progress toward novel therapeutics and provided discrete biochemical targets for drug screening and development.
Journal ArticleDOI

Pathological roles of MAPK signaling pathways in human diseases

TL;DR: Recent findings on the roles of MAPK signaling pathways in human disorders, focusing on cancer and neurodegenerative diseases including AD, PD, and ALS are summarized.
Journal ArticleDOI

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics.

TL;DR: It is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clinical trials will constitute a valid test of this hypothesis and explore whether amyloids-β-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.
Journal ArticleDOI

Intracellular amyloid-β in Alzheimer's disease

TL;DR: Although the classical view is that Aβ is deposited extracellularly, emerging evidence from transgenic mice and human patients indicates that this peptide can also accumulate intraneuronally, which may contribute to disease progression.
References
More filters
Journal ArticleDOI

Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production

TL;DR: C cultured cells which express a β-APP complementary DNA bearing a double mutation found in a Swedish FAD family produce ∼6–8-fold more Aβ than cells expressing normalβ-APP, and this increase is confirmed for elucidating the fundamental mechanism of Alzheimer's disease.
Journal ArticleDOI

A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid.

TL;DR: A double mutation at codons 670 and 671 (APP 770 transcript) in exon 16 which co–segregates with the disease in two large (probably related) early–onset Alzheimer's disease families from Sweden is identified.
Journal ArticleDOI

Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease

TL;DR: In this paper, levels of amyloid β-peptide (Aβ) were measured in brain regions of transgenic mice between 4 and 18 months of age, showing that Aβ levels dramatically and predictably increased in brain areas undergoing histochemically confirmed amyloidsosis, most notably in the cortex and hippocampus.
Related Papers (5)